Which of the following antigens are associated with cicatricial pemphigoid?
**Core Concept**
Cicatricial pemphigoid is a chronic autoimmune blistering disease characterized by the formation of cicatricial (scar) lesions due to autoantibody-mediated damage to the basement membrane zone of the skin and mucous membranes. The disease is associated with specific antigens that are targeted by the immune system, leading to tissue damage.
**Why the Correct Answer is Right**
The correct answer is associated with the antigens BPAG2 (bullous pemphigoid antigen 2) and epiligrin. BPAG2 is a component of the hemidesmosomal complex, which plays a crucial role in anchoring the basal keratinocytes to the basement membrane. Epiligrin is another component of the basement membrane that is targeted in cicatricial pemphigoid. The autoantibodies against these antigens lead to the disruption of the hemidesmosomal complex and the subsequent blistering of the skin and mucous membranes.
**Why Each Wrong Option is Incorrect**
**Option B:** HLA DR5 and HLA B8 are associated with autoimmune diseases such as autoimmune hepatitis and Sjögren's syndrome, but not specifically with cicatricial pemphigoid. They are not the correct antigens targeted in this disease.
**Option C:** HLA DR52 and HLA DR3 are associated with autoimmune thyroid disease and type 1 diabetes, respectively. They are not the correct antigens associated with cicatricial pemphigoid.
**Option D:** HLA DQB2 is not a recognized antigen associated with cicatricial pemphigoid. It is possible that this option is a distractor or a typographical error.
**Clinical Pearl / High-Yield Fact**
It is essential to remember that cicatricial pemphigoid is a chronic autoimmune disease that requires prompt recognition and treatment to prevent scarring and disfigurement. The presence of autoantibodies against BPAG2 and epiligrin is a key diagnostic feature of this disease, and a thorough histopathological examination is necessary to confirm the diagnosis.
**✓ Correct Answer: A. BPAG2 and epiligrin**